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a b s t r a c t 
Genetic rearrangements involving the anaplastic lymphoma kinase ( ALK ) gene create oncogenic drivers for sev- 
eral cancers, including malignant peritoneal mesothelioma (MPeM). Here, we report genomic and functional 
precision oncology profiling on a rare case of a 5-year old patient diagnosed with wide-spread and aggressive 
MPeM, driven by STRN-ALK rearrangement. We established genomically representative patient-derived cancer 
cells (PDCs) from the tumor sample and performed high-throughput drug sensitivity testing with 527 oncology 
compounds to identify potent inhibitors. As expected, the PDCs were overall sensitive to the ALK inhibitors, al- 
though the eight different inhibitors tested had variable efficacy. We also discovered other effective inhibitors, 
such as MEK/ERK inhibitors and those targeting pathways downstream of ALK as well as Bcl-xl inhibitors. In 
contrast, most cytotoxic drugs were not very effective. ALK inhibitors synergized with MEK and PI3K/mTOR 
inhibitors, highlighting potential combinatorial strategies to enhance drug efficacy and tackle drug resistance. 
Based on genomic data and associated functional validation, the patient was treated with the ALK inhibitor crizo- 
tinib in combination with conventional chemotherapy (cisplatin and gemcitabine). A complete disease remission 
was reached, lasting now for over 3 years. Our results illustrate a rare pediatric cancer case, and highlight the po- 
tential of functional precision oncology to discover pathogenetic drivers, validate dependency on driver signals, 
compare different inhibitors against each other and potentially enhance targeted treatments by drug combina- 
tions. Such real-time implementation of functional precision oncology could pave the way towards safer and more 





























Chromosomal rearrangements involving anaplastic lymphoma ki-
ase (ALK) are known oncogenic drivers encompassing multiple cancers,
ncluding lymphomas and non-small-cell lung cancer [1] . These translo-
ations involve diverse fusion partners that enable ALK autophosphory-
ation resulting in constitutively active tyrosine kinase that leads to aber-
ant activation of its downstream signaling pathways, such as RAS/ERK,
I3K/AKT and JAK/STAT [2] . Five ALK tyrosine kinase inhibitors have
een approved by the Food and Drug Administration (FDA) and Eu-
opean Medicines Agency (EMA) thus far. These include the first-Abbreviations: CRP, C-reactive protein levels; CRS, cytoreductive surgery; CT, co
ensitivity score; HIPEC, heated intraperitoneal chemotherapy; MPeM, malignant pe
hemotherapy; PDC, patient-derived cancer cells; PET-CT, positron emission tomogra
∗ Corresponding author. 
E-mail address: astrid.murumagi@helsinki.fi (A. Murumägi). 
ttps://doi.org/10.1016/j.tranon.2021.101027 
eceived 9 November 2020; Received in revised form 19 December 2020; Accepted 2
936-5233/© 2021 The Authors. Published by Elsevier Inc. This is an open access ar
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) eneration ALK inhibitor crizotinib (Xalkori), second-generation ALK in-
ibitors alectinib (Alecensa), brigatinib (Alunbrig) and ceritinib (Zyka-
ia), and recently approved third-generation ALK inhibitor lorlatinib
Lorviqua) [3] . In addition, several other ALK-targeting compounds are
urrently in preclinical or clinical development phases [4] . The admin-
stration of ALK inhibitors has produced remarkable clinical responses,
owever, often these have not been durable, due to the development of
esistance [5] . 
Fusion partner striatin ( STRN ) gene resulting in STRN-ALK was first
eported in 2014 in thyroid cancer and since then has been also detected
n non-small-cell lung cancer, colorectal cancer, malignant mesothe-mputed tomography; DSRT, drug sensitivity and resistance testing; DSS, drug 
ritoneal mesothelioma; MRI, magnetic resonance imaging; NACT, neoadjuvant 
phy-computed tomography. 
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p  ioma and recently in salivary intraductal carcinoma [6–10] . STRN-ALK
s a rare fusion gene, which mechanistically leads to constitutive acti-
ation of ALK tyrosine kinase and aberrant activation of several down-
tream signaling pathways such as MAPK/PI3K/STAT3 driving tumor
rogression [ 2 , 7 ]. 
Here, we report detection of STRN-ALK fusion in a 5-year old
ediatric patient diagnosed with widely spread malignant peritoneal
esothelioma (MPeM). Although occurrence of MPeM in young patients
s rare, STRN-ALK fusion has been reported before such as in a 12-year
ld MPeM patient [11] . Hung et al. analyzed the prevalence of ALK fu-
ions in adult MPeM and identified that 3% of patients in their cohort
ere ALK-positive, suggesting that ALK rearrangements play a role in
PeM pathogenesis [8] . MPeM is a rare and aggressive cancer, affecting
he mesothelial tissue of the peritoneum, pericardium and tunica vagi-
alis, with rare metastatic spread beyond the abdominal cavity [12] . The
isease is associated with poor prognosis due to late diagnosis and the
edian survival is less than 12 months for the majority of patients. The
tandard first-line treatment is cytoreductive surgery (CRS) with heated
ntraperitoneal chemotherapy (HIPEC). There are also novel agents in
linical trials such as inhibitors of the epidermal growth factor receptor,
ascular endothelial growth factor, mesothelin, and histone deacetylases
 12 , 13 ]. 
The application of functional ex vivo testing of patient-derived can-
er cells (PDCs) with a panel of oncology drugs has been suggested and
pplied for predicting the patients´ clinical response to targeted thera-
eutics. This is complementary to the standard precision oncology ap-
roach, which relies on the identification of actionable mutations of
river oncogenes by next-generation sequencing [ 14 , 15 ]. Here, we ap-
lied our functional precision medicine approach by integrating molec-
lar profiling data of cancer cells with the phenotypic drug response
rofile of PDCs ex vivo to explore therapeutic options for this rare cancer
orm. These data were then passed to the clinicians and could be con-
idered in helping the patient treatment regimens. Our results revealed
elective efficacy of several ALK inhibitors towards patients´ PDCs ex
ivo in 2D as well as in 3D condition. In addition, we identified several
ynergistic drug combinations that had stronger effect on cell viability
han ALK inhibitors alone. Combinations could be useful to prevent drug
esistance from arising and hence, therapeutic efficacy and durability of
he response. 
. Material and methods 
.1. Establishment of patient-derived cancer cell culture 
The patient material and clinical data were acquired under Institu-
ional Ethical Review Board-approved protocol (Dnro HUS/1880/2017)
nd in accordance with the Declaration of Helsinki. Informed consent
as obtained from the patient´s parent, including a permission to pub-
ish the patient case. Primary patient-derived cancer cell (PDC) culture
esignated as FM-MPeM-01 was established from diagnostic tumor biop-
ies. Briefly, fresh biopsies were processed to obtain single-cell suspen-
ion by enzymatic digestion using a Tumor Dissociation kit (Miltenyi
iotec) and gentleMACS Dissociator (Miltenyi Biotec). PDCs were estab-
ished and maintained in RPMI-1640 media (Gibco) supplemented with
EGF (20 ng/ml), hydrocortisone (1 𝜇g/ml), primocin (Invivogen) and
 % FBS at 37°C with 5% CO 2 . Majority of non-cancerous cells, mainly
tromal cells (referred to as Mixed culture) were removed during the
stablishment of PDCs by differential trypsinization and maintained in
PMI-1640 media supplemented with 5% FBS and primocin (Invivogen)
t 37°C with 5% CO 2 . All experiments were performed with low ( < 10)
assage cells and the culture was routinely tested for mycoplasma con-
amination using mycoplasma detection kit QuickTest (Biotool) accord-
ng the manufacturer´s instructions. 2 .2. Immunohistochemistry (IHC) and fluorescence in situ hybridization 
FISH) 
Tumor biopsy samples were formalin fixed and paraffin embedded
n the HUSLAB Pathology department according to standard procedures.
or IHC analysis, formalin-fixed paraffin-embedded (FFPE) blocks were
ut as 3.5 𝜇m sections and stained for antibodies against ALK (#3633,
ell Signaling Technology), CK7 (clone OV-TL 12/30, Agilent Dako),
alretinin (clone DAK-Calret 1, Agilent Dako), WT1 (#83535, Cell Sig-
aling Technology), CK5/6 (clone D5/16 B4, Agilent Dako), PAX8
#10336-1-AP, ProteinTech,) and ER (clone 1D5, Agilent Dako) using
rotocols for routine diagnostics. IHC stained sections were scanned
ith a high-resolution whole-slide scanner (Pannoramic 250 Flash III,
DHISTECH) with a x20 objective. The ALK rearrangement status of the
umor biopsy sample was evaluated by FISH in the HUSLAB Genetics
aboratory using ALK dual-color break-apart probe according to manu-
acturer’s protocol (Vysis, Abbott Molecular) 
.3. RT-PCR and sanger sequencing 
Total RNA was isolated from FM-MPeM-01 PDCs using RNeasy kit
Qiagen) and the quality of the RNA was assessed with Qubit fluorom-
ter (Thermo Fisher Scientific). 3 micrograms of total RNA was used
or the first strand cDNA synthesis using the High Capacity cDNA Re-
erse Transcription Kit (Applied Biosystems). RT-PCR was performed
ith Phusion Flash High-Fidelity PCR master mix (Thermo Fisher Scien-
ific). Verification of STRN-ALK fusion gene in FM-MPeM-01 PDCs was
arried out at the FIMM Technology Centre Sequencing Unit by capil-
ary sequencing. Primer sequences were the following: forward primer
´- CCACAAGTTGAAATACGGGACA and reverse primer 5´- ACTGATG-
AGGAGGTCTTGC. 
.4. Immunofluorescence 
Cells were cultured on 384-well high content imaging plates
PerkinElmer) and fixed with 4% PFA in PBS solution for 15 min at
T. Permeabilization was done with 0.1% Triton X in PBS for 10 min
t RT followed by 1 h blocking with 1% BSA in PBS. After washing
ith PBS, cells were incubated overnight at 4°C with CK7 (Clone OV-TL
2/30, Dako), pan-cytokeratin (ab9377, Abcam) and PDGF Receptor- 𝛽
#3169, Cell Signaling Technologies) antibodies followed by secondary
ntibodies, Alexa Fluor 488 Goat Anti-Mouse IgG (#A-11001) and Alexa
luor Plus 594 donkey anti-rabbit IgG (#A32754, Invitrogen, Thermo
isher Scientific), incubation for 1h at RT. The cells were counterstained
ith Hoechst 33342 (Invitrogen, Thermo Fisher Scientific). Images were
aken with PerkinElmer Opera Phenix automatic spinning-disk confocal
icroscope using a 20 x water objective, NA 1.0. 
.5. Western blot 
Whole cell lysates were prepared from FM-MPeM-01 PDCs and
ixed culture grown in 2D by lysing cells in ice cold lysis buffer (50
M Tris-HCl pH 7.5, 10 % glycerol, 150mM NaCl, 1 mM EDTA, 1%
riton-x-100, 50 mM NaF) supplemented with protease and phosphatase
nhibitor cocktails (Biotool). Cell lysates were incubated 20 min on ice
ollowed by 20 min centrifugation at 4°C. Cell pellets were resuspended
n SDS sample buffer and proteins were separated by sodium dode-
yl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and trans-
erred to nitrocellulose membranes. After blocking (5% BSA in 0.05%
ween20 in 1xTBS) at RT for 1h, blots were incubated with the in-
icated primary antibodies overnight at 4°C. Blots were washed three
imes with 1xTBS/0.1%Tween20 buffer and incubated with secondary
ntibodies for 1h at RT. Blots were scanned with Odyssey CLx Imaging
ystem (LI-COR) and images were processed with Image Studio Lite (LI-
OR). Following antibodies were used for western blot: ALK (#3633),
hospho-ALK (Tyr1282/1283, #3714), phospho-MEK1/2 (Ser217/221,



























































































































p  9121), ERK1/2 (#4696), phospho-ERK1/2 (Thr202/Tyr204, #9101),
hospho-JNK (Thr183/Tyr185, #9255), JNK (#9252) from Cell Signal-
ng Technology; MEK1/2 (#sc-6250) and 𝛽-tubulin (#sc-166729) from
anta Cruz Biotechnology. As secondary antibodies IRDye 800CW Don-
ey anti-Mouse IgG or IRDye 680RD Donkey anti-Rabbit IgG (LI-COR)
t 1:10000 dilution were used. 
.6. Drug sensitivity and resistance testing (DSRT) 
DSRT was performed with FM-MPeM-01 PDCs and Mixed culture
ith FIMM FO5 drug library containing 527 approved and investiga-
ional drugs (Supplemental Table S1A) as described previously [15] .
riefly, the drugs were dissolved in 100% dimethyl sulfoxide or wa-
er and plated in five concentrations covering a 10,000-fold range on
84-well flat clear bottom tissue culture treated microplates (Corning)
sing an Echo 550 acoustic dispenser (Labcyte). Cells were dispensed on
re-drugged plates with the Multidrop dispenser (Thermo Fisher Scien-
ific) and incubated for 72 hours at 37 °C at 5% CO 2 . Cell viability was
easured with Cell Titer-Glo Cell Viability Assay (Promega). Quantita-
ive dose response curves for each drug were generated as previously
escribed [15] . The drug efficacy was quantified with a modified area-
nder-the-curve measurement called drug sensitivity score (DSS), cal-
ulated and visualized as previously described [ 16 , 17 ]. For measuring
he drug responses for ALK inhibitors in 3D culture conditions, the assay
as carried out similarly, except PDCs or Mixed culture were seeded on
ltra-low attachment 384-well round bottom cell culture plates (Corn-
ng) pre-plated with drugs in nine increasing concentrations. Drug com-
ination testing was performed with selected drugs using drug concen-
ration matrices covering seven different concentrations. Highest single
gent (HSA) synergy model was applied for synergy assessment using
he R package SynergyFinder [18] . 
. Results 
.1. The patient´s clinicopathological features 
A 5-year old patient was referred to the Helsinki University Central
ospital because of weight loss, mild anemia and a rise in C-reactive
rotein levels (CRP). Abdominal ultrasound and magnetic resonance
maging (MRI) showed a large pelvic tumor mass and a second tumor
ass in the upper abdomen infiltrating to the liver ( Fig. 1 A). The tumor
ass had also spread below the spleen across the omentum and was sur-
ounded by ascites. The whole-body MRI, lung computed tomography
CT) and positron emission tomography-computed tomography (PET-
T) scans did not show any extra-abdominal metastasis. For diagnostic
urposes tumor biopsies were taken, however, primary operation was
ot possible because of the diffuse spread in abdomen. Conventional
hemotherapy with cisplatin and gemcitabine was started. The immuno-
istochemistry (IHC) analysis of multiple tumor biopsies revealed that
ancer cells stained positive for cytokeratin-7 (CK7) as well as Wilms’
umor protein 1 (WT1), calretinin and cytokeratin 5/6 (CK5/6), which
re markers frequently detected in both mesotheliomas and serous car-
inomas (Supplemental Fig. S1) [19] . Furthermore, tumor cells were
lso positive for the expression of paired box-protein (PAX8) and estro-
en receptor (ER), which are usually markers for serous ovarian can-
er (Supplemental Fig. S1). Taken together, the morphology based on
ematoxylin and eosin staining and the immunohistopathologic analy-
is of the tumor biopsies prompted us to establish a diagnosis of MPeM
 Fig. 1 B). Next-generation sequencing of the tumor biopsy with a tar-
eted Foundation One cancer panel revealed a STRN-ALK fusion gene
nd in line with this finding, we detected a strong ALK expression by
HC ( Fig. 1 C) and a chromosomal fusion event by fluorescence in situ
ybridization (FISH) ( Fig. 1 D) in tumor sample. STRN-ALK transloca-
ion is formed by exon 3 of STRN and exon 20 of ALK , retaining the ALK
yrosine kinase domain in the fusion protein, as reported also for other
atient cases with the same fusion [ 6 , 7 , 11 ]. Besides the identification3 f STRN-ALK fusion, the tumor was microsatellite stable and showed no
ther driver mutations and had a low overall mutation burden. 
.2. Drug sensitivity testing on representative patient-derived cancer cells 
Fresh tumor biopsy obtained for diagnostic purposes was processed
o establish a patient-derived cancer cell (PDC) culture designated as
M-MPeM-01 for functional analyses (Supplemental Fig. S2A). In paral-
el, primary cell culture consisting of mainly fibroblasts with few can-
er cells referred as a Mixed culture was also established from the same
iopsy sample (Supplemental Fig. S2B). FM-MPeM-01 PDCs stained pos-
tive for CK7 and pan-cytokeratin, which exhibited weak staining for
hese markers in Mixed culture (Supplemental Fig. S3). In contrast,
ixed culture cells were positive for PDGF 𝛽-receptor, commonly ex-
ressed in fibroblasts (Supplemental Fig. S3) [20] . To confirm the molec-
lar identity of PDCs with the original tumor sample, FM-MPeM-01
DCs were analyzed for the expression of STRN-ALK fusion gene by RT-
CR and Sanger sequencing, ALK expression by IHC and expression of
epresentative proteins of signaling pathways activated by ALK hyper-
ctivation such as phospho-MEK, phospho-ERK, phospho-JNK, by West-
rn blotting ( Fig. 1 E and F, Supplemental Fig. 2C and D). Western blot
nalysis showed the absence of phospho-ALK and lower expression of
ts downstream phospho-MEK/phospho-ERK in the Mixed culture cell
ysates compared to the PDCs (Supplemental Fig. S2D). To determine
he drug response profile of FM-MPeM-01, the PDCs and Mixed culture
ells were studied by a high-throughput drug sensitivity and resistance
esting (DSRT) platform with a panel of 527 approved drugs and emerg-
ng oncology compounds ( Fig. 2 A, Supplemental Table S1B). In addition
o the Mixed culture, as another control, we used DSRT data from two
ealthy bone marrow samples. To identify FM-MPeM-01 PDC-selective
rug efficacies, we correlated the drug responses of the PDC in relation
o both Mixed culture and healthy bone marrow samples ( Fig. 2 B). We
onsidered a selective drug sensitivity score (sDSS) above 5 as a hit.
SRT data revealed that FM-MPeM-01 PDCs were sensitive to ALK in-
ibitors, as expected. From eight ALK inhibitors included in the drug
ibrary, six displayed selective cancer cell-specific sensitivity, including
ll approved ALK inhibitors, with brigatinib, ensartinib and crizotinib
xhibiting highest sensitivities ( Fig. 2 C, Supplemental Fig. S4). Alec-
inib had a lower sDSS compared to the Mixed culture (sDSS 4.5), but
ad a higher sDSS compared to bone marrow control samples (sDSS
.4). The corresponding values for CEP-37440 were 4 and 7.9, respec-
ively. Among other drugs displaying selective sensitivity in FM-MPeM-
1 PDC were apoptotic inhibitors (such as navitoclax and investigational
ompounds A-1155463 and A-1331852) and small molecule kinase in-
ibitors targeting MAPK signaling pathway components (pan-RAF in-
ibitors TAK-530, cobimetinib and trametinib) ( Fig. 2 B-D, Supplemen-
al Fig. S4). In contrast, most cytotoxic drugs were not very effective,
ncluding gemcitabine and cisplatin (Supplemental Fig. S5). 
We also evaluated drug responses of PDCs grown in both 2D and
D conditions. We defined sensitivity to the eight ALK inhibitors in the
M-MPeM-01 PDC cultured as 3D spheroids (Supplemental Fig. 2A, Sup-
lemental Table S1C and S1D). FM-MPeM-01 PDCs displayed a higher
ensitivity to ALK inhibitors in 3D as compared to 2D, confirming the
ependency of the cancer cells to ALK hyperactivation driven oncogenic
ignaling ( Fig. 3 ). Six ALK inhibitors had DSS between 15 to 20.8, with
rigatinib displaying highest sensitivity (DSS 20.8), followed by ceri-
inib and crizotinib. A second-generation approved ALK inhibitor, alec-
inib, had lower response to FM-MPeM-01 PDCs, as compared to other
rugs, resulting in only 50% cell viability reduction in 3D assay as well
s lower response in 2D ( Fig. 3 ). 
.3. Identification of effective drug combinations targeting FM-MPeM-01 
DCs 
Inhibiting cancer-associated pathways with a single agent has often
roven to have limited clinical efficacy due to the development of resis-
A. Murumägi, D. Ungureanu, M. Arjama et al. Translational Oncology 14 (2021) 101027 
Fig. 1. Clinical profile and molecular characterization of the tumor. (A) Gadolinium-enhanced magnetic resonance image (MRI) scans of the patient´s abdomen 
before and after one year of treatment with chemotherapy and crizotinib. Images before the treatment showed a large pelvic mass and a mass infiltrating the liver 
surrounded by ascites (as indicated by red arrows). Follow-up images after one year of treatment with crizotinib in combination with chemotherapy, including 
tumor resection after 4 months of crizotinib combination treatment, shows complete disease remission. (B) Representative hematoxylin and eosin stained section of 
the tumor biopsy (original magnification x 10) (C) Representative IHC staining shows strong ALK expression in the tumor tissue (original magnification x 10). (D) 
Representative FISH image (100 x) showing ALK rearrangement (split red and green signals) in the tumor cells nuclei. (E) Confirmation of the STRN-ALK transcript in 
patient-derived cancer cells by RT-PCR. Also shown are size marker (M) and no-template control (NTC); and Sanger sequencing (F). Partial chromatogram showing 
the STRN-ALK transcript nucleic acid sequence where the break-point is indicated by an arrow. 
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A. Murumägi, D. Ungureanu, M. Arjama et al. Translational Oncology 14 (2021) 101027 
Fig. 2. Drug sensitivity profile of FM-MPeM-01 PDCs. (A) Schematic representation of the functional drug sensitivity testing platform where patient-derived cancer 
cells (PDCs) established from tumor biopsy are tested in the drug sensitivity and resistance (DSRT) assay with 527 drugs to identify patient-specific drug sensitivities. 
(B) Scatter plot showing the selective drug sensitivity (sDSS) scores of FM-MPeM-01 PDC in relation to healthy bone marrow controls (Y-axis) and Mixed culture 
(X-axis). ALK inhibitors are highlighted in red, MEK1/2 inhibitors in blue, apoptotic modulators in purple and other selective hits in turquoise. (C) Bar-plot graph 
showing the sDSS towards Mixed culture of the most effective drugs for FM-MPeM-01 PDCs. Highlighted are ALK inhibitors (red), RAF/MEK/ERK inhibitors (blue) 
and apoptotic modulators (purple). FM-MPeM-01 PDCs and Mixed culture cells underwent drug testing with 527 drugs at five concentrations for 72 hours. Cell 
viability was measured with the CellTiter-Glo luminescent cell viability assay. (D) Individual dose-response curves for drugs displaying higher selective responses in 
FM-MPeM-01 PDCs compared to Mixed culture and healthy bone marrow (BM) controls. 
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A. Murumägi, D. Ungureanu, M. Arjama et al. Translational Oncology 14 (2021) 101027 
Fig. 3. Different efficacies of ALK inhibitors towards FM-MPeM-01 PDCs in 3D. Dose-response curves for eight ALK inhibitors for FM-MPeM-01 PDCs and Mixed 
culture tested in 3D condition as spheroids. Individual IC50 and DSS values are shown for each drug, which were tested in 9 concentrations. Average of two replicates 





































a  ance, as it has been shown also for ALK-driven cancers [1] . Combining
rugs inhibiting several oncogenic signaling pathways is considered a
ore effective way to kill cancer cells and achieve remission [21] . Con-
equently, we tested various drug combinations targeting MAPK, PI3K
nd STAT pathways that are known to be upregulated in ALK-rearranged
ancers [2] . Drug combinations were tested on a dose-response matrix in
even concentrations and the SynergyFinder, a web-based application to
nalyze drug combination data, was used to detect any potential synergy
22] . We identified strong synergy between ALK inhibitors (crizotinib
nd ceritinib) in combination with MEK (cobimetinib) and mTOR/PI3K
gedatolisib) inhibitors, respectively ( Fig. 4 ). The synergy was more ef-
cient for ceritinib compared to crizotinib. These results highlight the
otential efficacy of these combinations in ALK-positive MPeM cancer
reatment if the resistance to ALK-targeting monotherapy would rise; in
ddition, the value of ex vivo PDCs in testing novel therapeutic agents
nd their combinations preclinically. 
.4. Patient response to personalized treatments 
Taking into consideration both molecular profiling and the valida-
ion by ex vivo drug sensitivity testing, crizotinib 1200 mg/week i.e. 116 g/kg/day was added to the neoadjuvant chemotherapy combination
reatment (cisplatin 60 mg/m 2 and gemcitabine 2000 mg/m 2 per cy-
le). The patient received six cycles of this combination. Six months af-
er initial diagnosis and treatment with a combination of chemotherapy
nd crizotinib, the residual tumor was resected. At the time of the resec-
ion, the pathological examination of the residual tumor revealed a small
ercentage of intact tumor cells. The treatment was continued after the
urgery for two cycles, followed by crizotinib monotherapy lasting for
ne year, until complete remission was achieved. In total, the patient
eceived crizotinib 1200 mg/week i.e. approximately 11 mg/kg/day for
bout 20 months. Currently, three-years after the initial diagnosis and
6 months after completion of treatment, there are no signs of resid-
al tumor by MRI and the patient is otherwise a healthy 8-year old girl
resenting normal growth and development. 
. Discussion 
Here we present the application of a genomic and functional preci-
ion medicine approach to identify and validate targeted treatment for
 5-year old pediatric patient case with a rare advanced MPeM carrying
A. Murumägi, D. Ungureanu, M. Arjama et al. Translational Oncology 14 (2021) 101027 
Fig. 4. Targeting MEK and ALK or MEK and PI3K/mTOR syn- 
ergistically inhibits FM-MPeM-01 PDCs growth. Dose-response 
curves of ALK inhibitors crizotinib (A, B) and ceritinib (C, D) 
alone or in combination with MEK inhibitor cobimetinib (A 
and C) and PI3K/mTOR inhibitor gedatolisib (B and D) in FM- 
MPeM-01 PDCs measured with cell viability assay after three 
days. Shown is one representative experiment of at least two 
replicates. 
7 






















































































































TRN-ALK fusion gene. Crizotinib treatment, along with chemotherapy
ed to complete disease remission, now lasting for over 3 years. 
Detection of ALK -rearrangements in MPeM suggests that for a small
ubgroup of patients with this cancer, encompassing particularly pedi-
tric cases, these fusions act as a driver of tumorigenesis making the
umor sensitive to targeted therapy [ 8 , 11 , 23 ]. STRN-ALK fusion was
ecently reported in another 12-year old MPeM pediatric patient case
ho had excellent response to second-generation ALK inhibitor ceri-
inib [11] . Promising ALK inhibitor responses have been reported also
n other tumor types with STRN-ALK fusion [ 7 , 24 –26 ]. However, in one
eport with this fusion detected in NSCLC, the patient was resistant to
LK inhibitor alectinib [6] . To date, more than 30 different ALK 5´fu-
ion partner genes have been identified and ALK translocations involv-
ng different partners and even different fusion points with the same
artner demonstrate distinct sensitivity to the structurally different ALK
nhibitors [27] . Childress et al. [27] studied seven distinct ALK-fusions
 STRN-ALK was not included) and showed that the 5´ partner affected
he biochemical and cellular properties of the ALK fusion protein, in-
luding kinase activity, protein stability, and, importantly, response to
LK inhibitor. Therefore, we consider it was relevant to test the efficacy
f eight ALK inhibitors, including approved and investigation ones, to-
ards FM-MPeM-01 PDCs. While all were efficacious, there was vari-
bility between the inhibitors. Crizotinib and ceritinib are both ATP-
ompetitive ALK tyrosine kinase inhibitors, except that crizotinib is also
 selective c-MET inhibitor and ceritinib inhibits also other receptors
ith lesser degree, such as IGF-1, insulin receptor and ROS [ 28 , 29 ]. Cer-
tinib was highly effective in patients with advanced, ALK -rearranged
SCLC, including those who had had disease progression during crizo-
inib treatment, indicating its efficacy as a second-generation ALK in-
ibitor [29] . Moreover, alectinib and brigatinib are also next-generation
LK inhibitors, showing superior activity over chemotherapy and crizo-
inib in recent studies in ALK-rearranged NSCLC [ 30 , 31 ]. 
Precision cancer therapy using ex vivo pharmacological testing of
DCs has shown great potential in identifying clinically translatable
reatments, especially for hematological malignancies [ 15 , 32 ]. There-
ore, functional testing of targeted drugs and drug combinations in
DCs could provide valuable confirmation of genomics-based precision
edicine. PDCs established from solid tumor tissue or ascites may rep-
esent a relevant model for predicting drug efficacy of patients, and they
an help to dissect molecular mechanisms of drug dependency across a
anel of similar or different drugs as well as their combinations [ 33 , 34 ].
ith our high-throughput drug testing platform we analyzed the re-
ponse profile of FM-MPeM-01 PDCs to 527 drugs, including approved
ncology drugs and investigational compounds. We showed that FM-
PeM-01 PDCs were sensitive to all eight ALK inhibitors included in
he drug panel, both in 2D and 3D conditions. This finding supported
he clinical use of ALK inhibitor in patient treatment. Three ALK in-
ibitors were approved by EMA in Europe at the time, crizotinib and
ewly approved alectinib and ceritinib. From these, crizotinib was cho-
en to be included for treatment based on clinical availability of the drug
t the local pediatric hospital. The patient responded well to the targeted
reatment and has now been in remission for three years from diagnosis,
ncluding a year after completion of treatment. Functional drug testing
ith PDCs revealed cancer cell vulnerabilities also to other targeted in-
ibitors beyond ALK, such as apoptotic inhibitors and MEK inhibitors.
ince acquired resistance to ALK inhibitors is a major obstacle in treating
LK-positive cancers, combination therapies that could improve ALK in-
ibitors efficacy warrant further research. We investigated this synergy
n our FM-MPeM-01 PDC model using MEK, PI3K and JAK inhibitors.
ombination treatment of ALKi with either MEK (cobimetinib) or PI3K
gedatolisib) inhibitors had a higher inhibitory effect in our FM-MPeM-
1 PDC model than ALK inhibitors alone, indicating that simultaneous
argeting of ALK and MEK or PI3K signaling pathway could potentially
mprove the efficacy of ALK inhibitors in MPeM and also could be ex-
lored in a clinical trial for patient treatment. 
 
8 . Conclusions 
In summary, we have demonstrated the feasibility of PDCs and the
elevance of functional drug testing in highlighting opportunities for
ersonalized cancer treatment. 
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